Skip to main content
. 2008 Jun 3;134(12):1267–1276. doi: 10.1007/s00432-008-0423-1

Table 2.

Relationship between LOH markers and clinicopathological characteristics

D14S67 D14S995 D14S65
LOH () (%) n = 23 (57.5) LOH (+) (%) n = 17 (42.5) P LOH () (%) n = 17 (44.7) LOH (+) (%) n = 21 (55.3) P LOH () (%) n = 28 (62.2) LOH (+) (%) n = 15 (37.8) P
Predictors
 Gender
  Male 18 (78.3) 14 (82.4) 1.00d 14 (82.4) 17 (81.0) 1.00d 24 (85.7) 14 (82.4) 1.00d
  Female 5 (21.7) 3 (17.6) 3 (17.6) 4 (19.0) 4 (14.3) 3 (17.6)
 Age
  Mean ± SD (years) 64.6 ± 8.9 62.2 ± 10.3 0.45c 63.1 ± 8.5 65.6 ± 10.5 0.46c 66.7 ± 9.2 60.3 ± 8.8 0.03 c
 Smokinge
  Yes 5 (25.0) 3 (17.6) 0.70d 2 (14.3) 4 (19.0) 1.00d 4 (16.0) 2 (11.8) 1.00d
  No 15 (75.0) 14 (82.4) 12 (85.7) 17 881.0) 16 (84.0) 15 (88.2)
 Alcohol intakee
  Yes 8 (42.1) 5 (33.3) 0.60b 4 (28.6) 8 (40.0) 0.72d 7 (31.8) 6 (35.3) 0.82b
  No 11 (57.9) 10 (66.7) 10 (71.4) 12 (60.0) 15 (68.2) 11 (64.7)
 TNM stagea, e
  Early stage (I–II) 5 (23.8) 5 (29.4) 0.73d 4 (28.6) 4 (19.0) 0.68d 6 (23.1) 5 (31.3) 0.72d
  Late stage (III–IV) 16 (76.2) 12 (70.6) 10 (71.4) 17 (81.0) 20 (76.9) 11 (68.7)
 Tumor stagee
  Early T (T1–T2) 7 (33.3) 7 (41.2) 0.62d 7 (50.0) 5 (23.8) 0.15d 9 (34.6) 6 (37.5) 0.85b
  Late T (T3–T4) 14 (66.7) 10 (58.8) 7 (50.0) 16 (76.2) 17 (65.4) 10 (62.5)
 Nodal stagee
  N (0) 11 (52.4) 9 (52.9) 0.97b 9 (64.3) 7 (33.3) 0.07b 11 (42.3) 10 (62.5) 0.20b
  N (+) 10 (47.6) 8 (47.1) 5 (35.7) 14 (66.7) 15 (57.7) 6 (37.5)
 Differentiatione
  Well 4 (16.0) 7 (43.8) 0.16d 4 (28.6) 8 (38.1) 0.72d 8 (32.0) 6 (37.5) 0.72b
  Moderate–poor 16 (80.0) 9 (56.3) 10 (71.4) 13 (61.9) 17 (68.0) 10 (62.5)
 Previous cancere
  With history 1 (5.6) 1 (6.3) 1.00d 1 (7.7) 2 (10.0) 1.00d 2 (8.7) 2 (12.5) 1.00d
  No history 17 (94.4) 15 (93.8) 12 (92.3) 18 (90.0) 21 (91.3) 14 (87.5)
 Secondary cancer
  With history 1 (5.6) 2 (12.5) 0.59d 1 (7.7) 4 (20.0) 0.62d 4 (17.4) 1 (6.3) 0.63d
  No history 17 (94.4) 14 (87.5) 12 (92.3) 16 (80.0) 19 (82.6) 15 (93.7)
 Family cancere
  With history 6 (33.3) 8 (50.0) 0.32b 6 (46.2) 8 (40.0) 0.73b 12 (52.2) 5 (31.3) 0.19b
  No history 12 (67.7) 8 (50.0) 7 (53.8) 12 (60.0) 11 (47.8) 11 (68.7)
 Local recurrencee
  Positive 3 (23.1) 6 (30.0) 1.00d 3 (23.1) 6 (30.0) 1.00d 6 (26.1) 5 (31.3) 0.73d
  Negative 10 (76.9) 14 (70.0) 10 (76.9) 14 (70.0) 17 (73.9) 11 (68.8)
 Local metastasise
  Positive 3 (23.1) 10 (50.0) 0.12c 3 (23.1) 10 (50.0) 0.12b 9 (39.1) 7 (43.8) 0.77d
  Negative 10 (76.9) 10 (50.0) 10 (76.9) 10 (50.0) 14 (60.9) 9 (56.3)
 Distant metastasise
  Positive 2 (15.4) 7 (35.0) 0.26d 2 (15.4) 7 (35.0) 0.26d 8 (34.8) 2 (12.5) 0.15d
  Negative 11 (84.6) 13 (65.0) 11 (84.6) 13 (65.0) 15 (65.2) 14 (87.5)

Bold indicates statistically significant P values

aAccording to the International Union Against Cancer 1997 TNM classification system

bChi-square test

cStudent’s t test

dFisher exact probability test

eCases with unknown history or record of smoking (three), alcohol consumption (three), TNM stage (three), recurrence (six), differentiation (four), previous cancer history (six), and family cancer history (six) were not included in the evaluation